

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司** \*  
(Incorporated in the Cayman Islands with limited liability)  
(Stock code: 1548)

## **INSIDE INFORMATION RECEIVING MILESTONE PAYMENT UNDER THE COLLABORATION AGREEMENT**

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (a) the inside information announcement of the Company dated 22 December 2017 in relation to the collaboration and license agreement (the “**Agreement**”) entered into among (i) Legend Biotech USA Inc., a non-wholly-owned subsidiary of the Company (“**Legend U.S.**”), (ii) Legend Biotech Ireland Limited, a non-wholly-owned subsidiary of the Company (“**Legend Ireland**”, together with Legend U.S., “**Legend**”) and (iii) Janssen Biotech, Inc. (“**Janssen**”) and one of its affiliate and (b) the announcements of the Company dated 17 December 2018, 28 July 2019, 28 January 2020, 21 December 2020, 21 May 2021, 11 February 2022, 21 April 2022, 15 August 2023 and 13 May 2024 on the achievement of certain milestones relating to the development of ciltacabtagene autoleucel, cilta-cel, now marketed in the United States under the brand name CARVYKT<sup>™</sup> and Legend’s entitlement to the milestone payments in the aggregate amount of US\$380 million paid by Janssen (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

The Board is pleased to announce that, in addition to the above, Legend received another milestone payment of US\$ 30 million under its collaboration agreement with Janssen for cilta-cel. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy.

To the best knowledge and belief of the Company, Janssen and one of its affiliate and their ultimate beneficial owners are third parties independent of the Company. The transactions

contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 28 June 2024

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Dai Zumian, Mr. Pan Jiuan, Dr. Wang Xuehai, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.*

*\* For identification purposes only*